Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (neutrophils) | 0.10 |
| chemistry Open Targets | compounds already reach it: navarixin anhydrous, reparixin, navarixin +4 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 6 Parkinson's papers of 3,839 | 0.74 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 7283
Sealed predictions
- CXCR2 in dopamine neurons, braak-0.21 (p 0.591) → -0.12 (p 0.767)receipt 7290
Swarm cases
receipt 7290: CXCR2 in dopamine neurons, braak
- power
- full sample -0.11 (p 0.652, n 18), 95% CI -0.55 to +0.37. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.11 (p 0.652, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.28 (p 0.269, n 18). could be the mix.
- skeptic
- leave-one-out range -0.22 to +0.01, sign flips 1; without severely affected donors -0.11 (p 0.652, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CXCR2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts